Plain-English translation of NCT05673928 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether and ado- (T-DM1)—two medications that target HER2-positive cancers—work better when given together to people whose cancer has spread to the brain. The researchers want to see if this combination can shrink brain tumors and help patients live longer. This is an important question because brain metastases are difficult to treat and few therapies have been proven effective for this specific situation.
Many cancer patients develop tumors in the brain, which is a serious complication that limits treatment options. This medication combination has shown promise against HER2-positive cancers, but it hasn't been thoroughly tested in patients whose cancer has spread to the brain, so researchers want to learn if it can help this group of patients.
You likely qualify if…
You likely don't qualify if…
You would take tablets by mouth twice daily and receive T-DM1 as an intravenous infusion once every 3 weeks. Each treatment cycle lasts 21 days. During the study, you'll have regular blood tests, imaging scans of your brain and other parts of your body, and heart function tests to monitor how you're responding and check for side effects. The study aims to enroll 30 patients total.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
M.D. Anderson Cancer Center
Collaborators
Genentech, Inc., Seagen Inc.
Enrollment target
~30 participants
Started
May 2023
Primary completion
March 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ecaterina Dumbrava, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.